Core Insights - The report maintains a positive outlook on the pharmaceutical and biotechnology sector, with a focus on raw material prices as of July 2025 [1][3] Hormonal Drug Price Situation - In July 2025, prices for hormonal drugs such as progesterone, medroxyprogesterone acetate, saponin, dexamethasone sodium phosphate, hydrocortisone, and acetate hydrocortisone remained stable month-on-month. Year-on-year, progesterone prices remained unchanged, while medroxyprogesterone acetate, saponin, dexamethasone sodium phosphate, hydrocortisone, acetate hydrocortisone, and saponin saw declines of 1.85%, 3.23%, 84.22%, 14.04%, 12.15%, and 5.66% respectively [6][10] Antibiotic Intermediate Price Situation - In July 2025, prices for antibiotic intermediates such as 4-AA remained stable month-on-month, while 7-ADCA, 7-ACA, 6-APA, and penicillin industrial salt saw decreases of 1.92%, 2.08%, 8.33%, and 7.89% respectively. Year-on-year, 7-ADCA, 7-ACA, 6-APA, 4-AA, and penicillin industrial salt prices fell by 1.92%, 4.08%, 45.00%, 13.92%, and 41.67% respectively [10][11] β-Lactam Antibiotic Price Situation - In July 2025, prices for β-lactam antibiotics such as cephalexin, ampicillin, cefotaxime sodium, and cefaclor remained stable month-on-month. However, ceftriaxone sodium, cefixime, and amoxicillin saw declines of 1.55%, 1.37%, and 11.36% respectively. Year-on-year, cephalexin, ampicillin, ceftriaxone sodium, cefotaxime sodium, cefixime, and amoxicillin prices decreased by 1.82%, 2.22%, 9.29%, 3.40%, 12.20%, and 35.00% respectively, while cefaclor saw an increase of 6.12% [15][17] Cardiovascular Drug Price Situation - In July 2025, prices for cardiovascular raw materials such as valsartan, irbesartan, telmisartan, lisinopril, enalapril maleate, and atorvastatin calcium remained stable month-on-month. Year-on-year, valsartan prices decreased by 1.54%, while the other drugs remained unchanged [19][20]

Core Viewpoint - The article highlights the successful mid-term handover of a large-scale ultra-high molecular weight polyethylene (UHMWPE) project in China, marking a significant advancement in the country's coal-based chemical industry [1][2]. Group 1: Project Overview - The project, located in Pucheng, has a production capacity of 40,000 tons per year and is the first large-scale industrial facility for coal-based UHMWPE in the country [2]. - The technology used in the project was developed through collaboration between the Shanghai Institute of Organic Chemistry and Sinopec Shanghai Engineering Company, utilizing ethylene and hydrogen as raw materials [2]. Group 2: Company Background - Pucheng Clean Energy Chemical Co., Ltd. was established in November 2008, funded by Shaanxi Coal and Chemical Industry Group and China Three Gorges Corporation, focusing on modern coal chemical and petroleum chemical integration [2]. Group 3: Industry Context - The global UHMWPE market is experiencing rapid growth, with key applications in lithium battery separators, medical materials, and fibers driving demand [3]. - Current domestic UHMWPE production capacity is approximately 270,000 tons per year, with an additional 320,000 tons under construction and plans for 480,000 tons of new capacity, totaling over 1 million tons [3]. - The MTO and olefin separation project aims to enhance processing capacity by 30%, producing 848,800 tons of double olefins annually, which will extend the olefin industry chain into high-value-added materials [3].